Myoblast transplantation: A possible surgical treatment for a severe pediatric disease

Surgery Today

Volumn 40, Issue 10, 2010, Pages 902-908

  Palmieri, Beniamino ^a   Tremblay, Jacques P ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Université Laval   (Canada)

Author keywords

Cyclosporine; Duchenne muscular dystrophy; Exon skipping; Myoblast; Tacrolimus

Indexed keywords

ALLOTRANSPLANTATION; CELL TRANSPLANTATION; CHILD; CHILDHOOD DISEASE; DUCHENNE MUSCULAR DYSTROPHY; GENE THERAPY; HUMAN; MUSCLE INJURY; MYOBLAST; NONHUMAN; PHENOTYPE; REVIEW; HOSPITALIZATION; METHODOLOGY; TRANSPLANTATION; TREATMENT OUTCOME;

CELL TRANSPLANTATION; CHILD; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; MYOBLASTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79952278465     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-009-4242-z     Document Type: Review

References (56)

1. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919–928.
2. Petrof BJ. Molecular pathophysiology of myofiber injury in deficiencies of the dystrophin-glycoprotein complex. Am J Phys Med Rehabil 2002;81:S162–S174.
3. Wynford-Thomas D. Replicative senescence: mechanisms and implications for human cancer. Pathol Biol (Paris) 2000;48:301–307.
4. Blau HM, Webster C, Pavlath GK. Defective myoblasts identified in Duchenne muscular dystrophy. Proc Natl Acad Sci USA 1983;80:4856–4860.
5. Péault B, Rudnicki M, Torrente Y, Cossu G, Tremblay JP, Partridge T, et al. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 2007;15:867–877.
6. Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 1989;337:176–179.
7. Vilquin JT, Asselin I, Guerette B, Kinoshita I, Lille S, Roy R, et al. Myoblast allotransplantation in mice: degree of success varies depending on the efficacy of various immunosuppressive treatments. Transplant Proc 1994;26:3372–3373.
8. Morgan JE, Partridge TA. Cell transplantation and gene therapy in muscular dystrophy. Bioessays 1992;14:641–645.
9. Kinoshita I, Vilquin JT, Guerette B, Asselin I, Roy R, Tremblay JP. Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle Nerve 1994;17:1407–1415.
10. Kinoshita I, Roy R, Dugré FJ, Gravel C, Roy B, Goulet M, et al. Myoblast transplantation in monkeys: control of immune response by FK506. J Neuropathol Exp Neurol 1996;55:687–697.
11. Skuk D, Roy B, Goulet M, Tremblay JP. Successful myoblast transplantation in primates depends on appropriate cell delivery and induction of regeneration in the host muscle. Exp Neurol 1999;155:22–30.
12. Skuk D, Goulet M, Roy B, Tremblay JP. Myoblast transplantation in whole muscle of nonhuman primates. J Neuropathol Exp Neurol 2000;59:197–206.
13. Skuk D, Tremblay JP. Progress in myoblast transplantation: a potential treatment of dystrophies. Microsc Res Tech 2000;48:213–222.
14. Skuk D, Goulet M, Roy B, Tremblay JP. Efficacy of myoblast transplantation in non-human primates following simple intramuscular cell injections: towards defining strategies applicable to humans. J Exp Neurrol 2002;175:112–126.
15. Gussoni E, Pavlath GK, Lanctot AM, Sharma KR, Miller RG, Steinman L, et al. Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature 1992;356:435–438.
16. Miller RG, Sharma KR, Pavlath GK, Gussoni E, Mynhier M, Lanctot AM, et al. Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study. Muscle Nerve 1997;20:469–478.
17. Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW, et al. Myoblast transfer in the treatment of Duchenne’s muscular dystrophy [see comments]. N Engl J Med 1995;333:832–838.
18. Karpati G, Ajdukovic D, Arnold D, Gledhill RB, Guttmann R, Holland P, et al. Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol 1993;34:8–17.
19. Tremblay JP, Malouin F, Roy R, Huard J, Bouchard JP, Satoh A, et al. Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant 1993;2:99–112.
20. Tremblay JP, Bouchard JP, Malouin F, Théau D, Cottrell F, Collin H, et al. Myoblast transplantation between monozygotic twin girl carriers of Duchenne muscular dystrophy. Neuromuscul Disord 1993;3:583–592.
21. Huard J, Bouchard JP, Roy R, Malouin F, Dansereau G, Labrecque C, et al. Human myoblast transplantation: preliminary results of 4 cases. Muscle Nerve 1992;15:550–560.
22. Neumeyer AM, Cros D, McKenna-Yasek D, Zawadzka A, Hoffman EP, Pegoraro E, et al. Pilot study of myoblast transfer in the treatment of Becker muscular dystrophy. Neurology 1998;51:589–592.
23. Vilquin JT, Kinoshita I, Roy R, Tremblay JP. Cyclophosphamide immunosuppression does not permit successful myoblast allotransplantation in mouse. Neuromuscul Disord 1995;5:511–517.
24. Gussoni E, Blau HM, Kunkel LM. The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat Med 1997;3:970–977.
25. Hong F, Lee J, Song JW, Lee SJ, Ahn H, Cho JJ, et al. Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity. FASEB J 2002;16:1633–1635.
26. Boulanger A, Asselin I, Roy R, Tremblay JP. Role of non-major histocompatibility complex antigens in the rejection of transplanted myoblasts. Transplantation 1997;63:893–899.
27. Skuk D, Caron NJ, Goulet M, Roy B, Tremblay JP. Resetting the problem of cell death following muscle-derived cell transplantation: detection, dynamics and mechanisms. J Neuropathol Exp Neurol 2003;62:951–967.
28. Hodgetts SI, Grounds MD. Complement and myoblast transfer therapy: donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5. Immunol Cell Biol 2001;79:231–239.
29. Beauchamp JR, Morgan JE, Pagel CN, Partridge TA. Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. J Cell Biol 1999;144:1113–1122.
30. Fan Y, Maley M, Beilharz M, Grounds M. Rapid death of injected myoblasts in myoblast transfer therapy. Muscle Nerve 1996;19:853–860.
31. Skuk D, Paradis M, Goulet M, Tremblay JP. Ischemic central necrosis in pockets of transplanted myoblasts in nonhuman primates: implications for cell-transplantation strategies. Transplantation 2007;84:1307–1315.
32. Karpati G, Ajdukovic D, Arnold D, Gledhill RB, Guttmann R, Holland P, et al. Myoblast transfer in Duchenne muscular dystrophy [see comments]. Ann Neurol 1993;34:8–17.
33. Skuk D, Goulet M, Roy B, Chapdelaine P, Bouchard JP, Roy R, et al. Dystrophin expression in muscles of Duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. J Neuropathol Exp Neurol 2006;65:371–386.
34. Skuk D, Goulet M, Roy B, Piette V, Côté CH, Chapdelaine P, et al. First test of a “high-density injection” protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up. Neuromuscul Disord 2007;17:38–46
35. Morgan JE, Pagel CN, Sherratt T, Partridge TA. Long-term persistence and migration of myogenic cells injected into preirradiated muscles of mdx mice. J Neurol Sci 1993;115:191–200.
36. Yao SN, Kurachi K. Implanted myoblasts not only fuse with myofibers but also survive as muscle precursor cells. J Cell Sci 1993;105:957–963.
37. Ehrhardt J, Brimah K, Adkin C, Partridge T, Morgan J. Human muscle precursor cells give rise to functional satellite cells in vivo. Neuromuscul Disord 2007;17:631–638.
38. Wang Z, Allen JM, Riddell SR, Gregorevic P, Storb R, Tapscott SJ, et al. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 2007;18:18–26.
39. van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den Dunnen JT, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 2001;10:1547–1554.
40. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT, et al. Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 2004;74:83–92.
41. Wells KE, Fletcher S, Mann CJ, Wilton SD, Wells DJ. Enhanced in vivo delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx mouse muscle. FEBS Lett 2003;552:145–149.
42. Moulton HM, Fletcher S, Neuman BW, McClorey G, Stein DA, Abes S, et al. Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem Soc Trans 2007;35:826–828.
43. Adams AM, Harding PL, Iversen PL, Coleman C, Fletcher S, Wilton SD. Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Mol Biol 2007;8:57.
44. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP, et al. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 2007;15:1587–1592.
45. Sampaolesi M, Blot S, D’Antona G, Granger N, Tonlorenzi R, Innocenzi A, et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006;444:574–579.
46. Brussee V, Merly F, Tardif F, Tremblay JP. Normal myoblast implantation in MDX mice prevents muscle damage by exercise. Biochem Biophys Res Commun 1998;250:321–327.
47. Ellis D. Clinical use of tacrolimus (FK-506) in infants and children with renal transplants. Pediatr Nephrol 1995;9:487–494.
48. Jain A, Mazariegos G, Kashyap R, Green M, Gronsky C, Starzl TE, et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation 2000;70:617–625.
49. English RF, Pophal SA, Bacanu SA, Fricker J, Boyle GJ, Ellis D, et al. Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. Am J Transplant 2002;2:769–773.
50. Hasenbein W, Albani J, Englert C, Spehr A, Grabhorn E, Kemper MJ, et al. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation. Pediatr Transplant 2006;10:938–942.
51. Atkison P, Joubert G, Barron A, Grant D, Paradis K, Seidman E, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995;345:894–896.
52. Filler G. Calcineurin inhibitors in pediatric renal transplant recipients. Paediatr Drugs 2007;9:165–174.
53. Asante-Korang A, Boyle GJ, Webber SA, Miller SA, Fricker FJ. Experience of FK506 immune suppression in pediatric heart transplantation: a study of long-term adverse effects. J Heart Lung Transplant 1996;15:415–422.
54. Camirand G, Stephan L, Rousseau J, Sackett MK, Caron NJ, Mills P, et al. Central tolerance to myogenic cell transplants does not include muscle neoantigens. Transplantation 2008;85:1791–1801.
55. Stephan L, Pichavant C, Bouchentouf M, Mills P, Camirand G, Tagmouti S, et al. Induction of tolerance across fully mismatched barriers by a nonmyeloablative treatment excluding antibodies or irradiation use. Cell Transplant 2006;15:835–846.
56. Camirand G, Rousseau J, Ducharme ME, Rothstein DM, Tremblay JP. Novel Duchenne muscular dystrophy treatment through myoblast transplantation tolerance with anti-CD45RB, anti-CD154 and mixed chimerism. Am J Transplant 2004;4:1255–1265.